BrightPath Biotherapeutics Co., Ltd. (TYO:4594)
Japan · Delayed Price · Currency is JPY 51.00
0.00 (0.00%)
Aug 6, 2026, 1:46 PM JST
TYO:4594 Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Net Income | -1,305 | -1,151 | -1,168 | -1,573 | -1,116 |
Depreciation & Amortization | - | - | 0.4 | 73 | 41 |
Loss (Gain) From Sale of Assets | -0.4 | - | - | - | - |
Asset Writedown & Restructuring Costs | 9.4 | 1.37 | 7.25 | - | - |
Other Operating Activities | 71.97 | 8.57 | 0.7 | -3 | 13 |
Change in Accounts Receivable | 1.09 | -1.14 | 0.05 | -22 | 51 |
Change in Inventory | - | - | - | 14 | -6 |
Change in Accounts Payable | -0 | 0.02 | -0.06 | -13 | -41 |
Change in Other Net Operating Assets | -142.96 | -108.02 | 2.82 | -67 | -9 |
Operating Cash Flow | -1,366 | -1,250 | -1,157 | -1,591 | -1,067 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Capital Expenditures | -0.59 | -1.37 | -6.19 | -108 | -97 |
Cash Acquisitions | - | - | - | - | 7 |
Sale (Purchase) of Intangibles | - | - | -1.45 | -3 | -6 |
Other Investing Activities | -1.34 | - | - | - | - |
Investing Cash Flow | -1.93 | -1.37 | -7.65 | -111 | -96 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Short-Term Debt Issued | - | 500 | 500 | - | - |
Total Debt Issued | - | 500 | 500 | - | - |
Short-Term Debt Repaid | -25 | -587.5 | -387.5 | - | - |
Total Debt Repaid | -25 | -587.5 | -387.5 | - | - |
Net Debt Issued (Repaid) | -25 | -87.5 | 112.5 | - | - |
Issuance of Common Stock | 2,739 | 1,093 | 578.46 | 3,281 | 3,559 |
Repurchase of Common Stock | -0 | -1.04 | - | - | - |
Other Financing Activities | -0 | -0 | 0 | - | - |
Financing Cash Flow | 2,714 | 1,005 | 690.96 | 3,281 | 3,559 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Miscellaneous Cash Flow Adjustments | -0 | - | - | -1 | -1 |
Net Cash Flow | 1,346 | -246.89 | -473.61 | 1,578 | 2,395 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Free Cash Flow | -1,366 | -1,252 | -1,163 | -1,699 | -1,164 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -1626716.67% | -110479.17% | -1615436.11% | -479.94% | -220.04% |
Free Cash Flow Per Share | -12.25 | -15.36 | -18.13 | -44.44 | -34.22 |
Levered Free Cash Flow | -892.46 | -836.04 | - | -1,029 | - |
Unlevered Free Cash Flow | -892.46 | -836.04 | - | -1,029 | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Cash Income Tax Paid | 1.9 | 1.9 | 1.9 | 3 | 2 |
Change in Working Capital | -141.87 | -109.14 | 2.81 | -88 | -5 |